Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Urges FDA To Prohibit Generic Exclusivity Transfer For Gabapentin

Executive Summary

Allowing generic drug companies to use "first-to-file" exclusivity as a licensable asset will lead to "speculative" ANDA filings, Pfizer warned in a citizen petition seeking to block approval of Teva's generic version of gabapentin (Neurontin)
Advertisement

Related Content

Pfizer Accupril Patent Victory Could Lead To Influx Of Generics In 2005
Pfizer Accupril Patent Victory Could Lead To Influx Of Generics In 2005
Teva, Ivax Move Closer To Marketing Generic Gabapentin
Teva, Ivax Move Closer To Marketing Generic Gabapentin
Advertisement
UsernamePublicRestriction

Register

PS044080

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel